Thank you, healthcare workers, for all you do. Your determination to help others is truly inspiring. Please stay safe.
Med-IQ
Perspectives in CHL Treatment: Addressing the Needs of Community Oncologists

Perspectives in CHL Treatment: Addressing the Needs of Community Oncologists

Med-IQ Select
Online Course | Specialties: Hematology, Oncology
Released: 9/21/2020
|
Expires: 9/20/2021
|
Max Credits: 0.5
Jump to Education

Faculty
Christopher Yasenchak, MD
Associate Chair, Hematology Research Program of US Oncology Research
Willamette Valley Cancer Institute and Research Center
Eugene, OR

Patrick B. Johnston, MD, PhD
Associate Professor of Medicine
Consultant, Division of Hematology
Department of Internal Medicine
Mayo Clinic
Rochester, MN
 
Activity Planners
Stephanie Larson, PhD
Clinical Content Manager
Med-IQ
Baltimore, MD

Samantha Gordon
Accreditation Manager
Med-IQ
Baltimore, MD

Amy Sison
Director of CME
Med-IQ
Baltimore, MD
  
Learning Objectives
Upon completion, participants should be able to:

  • Tailor treatment plans for patients with CHL based on patient-, disease-, and treatment-related factors
  • Align clinical practice patterns in accordance with the latest clinical evidence, guideline recommendations, and expert perspectives for the management of patients with CHL

Target Audience
This activity is intended for community hematologists and oncologists.
 
Statement of Need
Novel treatment regimens are available for patients with CHL, but staying up-to-date on new treatment approaches can be challenging for busy clinicians, creating an additional barrier to the integration of these new options into the standard of care. The majority of cancer care within the United States is delivered within the community setting. However, data reveal differences in treatment selection strategies between community and academic cancer centers, suggesting that the provision of high-quality, evidence-based care may depend on the setting in which treatment is received. This activity aims to explore the unique challenges faced by community hematologists and oncologists and provide support for these physicians in integrating novel treatment strategies into their care of patients with CHL.

Providership Statement
Provided by Med-IQ. 
 
Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
 
Medium/Method of Participation
This is a 0.5-credit CME activity. To receive credit, read the introductory CME material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: September 21, 2020
Expiration Date: September 20, 2021
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Chris Yasenchak, MD
Consulting fees/advisory boards/steering committee: Bristol-Myers Squibb, Seattle Genetics
Fees received for promotional/non-CME activities: BeiGene, Seattle Genetics, Takeda Pharmaceuticals North America, Inc.
Contracted research: Seattle Genetics

Patrick B. Johnston, MD, PhD, has indicated no real or apparent conflicts.

The peer reviewers and activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
 
Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-policy.html.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Seattle Genetics, Inc.
 
Copyright
© 2020 Med-IQ, Inc.

Abstract

Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available at the continue button below.

Community oncologists and hematologists, who provide care for the majority of patients with cancer, face unique obstacles in the treatment of classic Hodgkin lymphoma (CHL). Although treatment for CHL is typically successful, with standard approaches resulting in long-term remission in approximately 80% of patients, challenges related to diagnosis and management still remain, including the low incidence rate of CHL, clinicians’ limited familiarity of guidelines, and older patient population. Additionally, community oncologists may not be aware of recently approved immunotherapeutic strategies that have demonstrated better outcomes and are associated with fewer treatment-related toxicities than standard therapies.

Module 1: CHL Care: Unique Challenges and Strategies for Community Oncologists

  • Challenges faced by community oncologists in the diagnosis and treatment of patients with CHL include low likelihood of seeing patients with CHL, limited pathology resources, limited staff, and lack of familiarity with standard therapies and novel immunotherapies
  • Faculty experts present strategies to address challenges faced in the community setting and discuss supportive educational materials for patients with newly diagnosed CHL

Module 2: First-Line Treatment–Related Challenges in the Community Setting

  • The preferred guideline-recommended first-line chemotherapy regimens for CHL are doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD), doxorubicin/vinblastine/dacarbazine (AVD), escalated bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisoe BEACOPP, and brentuximab vedotin (BV) + AVD
  • Faculty experts discuss their experience with using preferred chemotherapy regimens and including growth factor support in select patient groups

Module 3: Community-Specific Challenges Associated With Managing Recurrent Disease

  • The preferred guideline-recommended second-line regimens for CHL are BV + bendamustine, BV + nivolumab, and rituximab in combination with second-line therapy options in relapsed/refractory nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)
  • Faculty experts explore key clinical trial data involving patients with recurrent disease and discuss the integration of newly available therapeutic strategies into treatment plans

Click "Continue" to proceed through this activity and/or receive credit. Or, select a specific module from the menu on the left. To receive credit and a certificate, you must complete all of the modules in this activity.

By clicking "Continue," you confirm that you have reviewed the CME information.
Continue
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.